Examoto
- Company typePrivate
- Founded2012
- HeadquartersBryn Mawr, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
Examoto firmographics
Firmographics- Name
- Examoto
- Legal name
- Examoto, LLC
- Website
- https://examoto.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Examoto industry classification
Industry- Product category
- Pharmaceutical Compliance Software
- NAICS
- Other Scientific and Technical Consulting Services (541690)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Pharmacovigilance & Drug Safety Software (HLAGAJAK)
- akta.pro secondary industries
- Clinical Trial Management Systems (CTMS) (HLACAOAD), Value Dossier & Evidence Generation (AMCP/Global Value Dossier) (HLAIAKAC)
Keywords
Where Examoto is headquartered
LocationHeadquarters
- HQ city
- Bryn Mawr
- HQ country
- United States
- HQ region
- North America
Markets served
Examoto business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations
Examoto product offering
Product offeringCore offering
Examoto designs, develops, deploys, and operates a technology-driven Risk Evaluation and Mitigation Strategy (REMS) platform for the pharmaceutical market. The platform delivers REMS services across multiple channels—including web, mobile, data, voice, SMS, and chat—for public digital environments, enabling pharmaceutical sponsors to meet FDA-mandated REMS requirements while maximizing the benefits and safe use of prescription drugs.
Product overview
Examoto offered a single unified technology platform focused exclusively on REMS (Risk Evaluation and Mitigation Strategy) compliance for the pharmaceutical industry. The platform provided end-to-end REMS services including web applications, mobile solutions, data management, voice systems, SMS, and chat capabilities across public digital environments. After being acquired by UBC (United BioSource LLC) in July 2022, Examoto's technology was integrated with UBC's Project Management Office and existing REMS services to create a comprehensive risk mitigation solution for biopharmaceutical sponsors.
Differentiator
Problem solved
Functional benefit
Products and services
- Examoto REMS Platform A comprehensive Risk Evaluation and Mitigation Strategy (REMS) technology platform for the pharmaceutical industry that enables the design, development, deployment, and streamlined operation of technologically driven REMS services across web, mobile, data, voice, SMS, and chat channels for public digital environments. It is intended for pharmaceutical and biopharmaceutical sponsors that need FDA-mandated REMS compliance.
Companies that use Examoto
Customer profileSegments1 record
Ideal customer profiles1 record
Examoto technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Examoto partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- UBC (United BioSource LLC)coreUBC acquired Examoto, LLC on July 28, 2022 to expand its position as leader in REMS services. The combination of Examoto's technology-driven approach with UBC's scientific, technological, and operational expertise creates the most comprehensive REMS capabilities for the biopharmaceutical industry. Examoto's technology and design innovations, combined with UBC's Project Management Office and related REMS services, creates a REMS powerhouse providing sponsors with single point of responsibility for clinical programs.
Recent moves2 records
Examoto competitors and assessment
Company assessmentBroad incumbents
- Veeva Systems: Veeva provides a broad life-sciences cloud platform (Vault) covering clinical, regulatory, safety, and quality. Its safety and quality modules overlap with REMS-adjacent functionality, making it a broad incumbent in Examoto's space.
- Honeywell (Sparta Systems) TrackWise: Honeywell's TrackWise (formerly Sparta Systems) is a quality management system widely used in life sciences for deviation, CAPA, and risk workflows — capabilities that intersect with the compliance backbone supporting REMS programs.
- Clario (formerly Bioclinica): Clario provides clinical trial technology and eCOA/ePRO solutions, with capabilities in safety and risk management that intersect with REMS workflows. It serves similar biopharma sponsors with broader clinical technology offerings.
- Cognizant Life Sciences / Medidata (Dassault Systèmes): Medidata's clinical trial platform (now part of Dassault Systèmes) supports RAVE, eCOA, and safety data capture used by biopharma sponsors, with adjacent functionality to REMS-related clinical program workflows.
- Oracle Health Sciences: Oracle offers Argus Safety and broader clinical/pharmacovigilance software used by large pharma sponsors. Its drug safety suite competes for the same regulatory-compliance technology budgets as Examoto's REMS platform.
Direct peers
- ArisGlobal: ArisGlobal's LifeSphere platform provides pharmacovigilance, drug safety, and regulatory software used by biopharma sponsors. It overlaps directly with Examoto's REMS-adjacent drug safety and compliance technology focus.
- Endpoint Clinical (now part of Accenture): Endpoint Clinical provides interactive response technology (IRT/RTSM) and clinical technology, with explicit REMS program capabilities for sponsors — directly comparable to Examoto's REMS platform functionality.
- United BioSource (UBC): UBC acquired Examoto in 2022 and is now its parent. UBC offers integrated clinical, safety, and commercialization services to biopharma sponsors, including dedicated REMS services — making it the closest direct peer and the platform through which Examoto's technology is now commercialized.
Emerging players
- AB Cube: AB Cube offers SafetyEasy, a pharmacovigilance and drug safety software platform used by life-sciences companies. It is a more focused emerging player in the drug safety software category adjacent to REMS.
- Bio-Optronics: Bio-Optronics provides Clinical Conductor CTMS and related clinical trial management technology for research sites and sponsors. Its workflow tooling for clinical programs overlaps tangentially with REMS program operations.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights5 records
Customer concentration
Examoto financial estimates
Financial estimateRevenue estimate
Valuation estimate
Examoto leadership team
Management profileNumber of profiles
Profiles1 record
Examoto funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Examoto M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Examoto
What does Examoto do?
Examoto designs, develops, deploys, and operates a technology-driven Risk Evaluation and Mitigation Strategy (REMS) platform for the pharmaceutical market. The platform delivers REMS services across multiple channels—including web, mobile, data, voice, SMS, and chat—for public digital environments, enabling pharmaceutical sponsors to meet FDA-mandated REMS requirements while maximizing the benefits and safe use of prescription drugs.
Is Examoto a public or private company?
Examoto is a private company. It is classified as corporate owned and is currently acquired.
When was Examoto founded?
Examoto was founded in 2012. It employs 1 to 10 people.
Where is Examoto based?
Examoto is headquartered in Bryn Mawr, United States, in the North America region.
Who are Examoto's main competitors?
Broad incumbents on record are Veeva Systems, Honeywell (Sparta Systems) TrackWise, Clario (formerly Bioclinica), Cognizant Life Sciences / Medidata (Dassault Systèmes) and Oracle Health Sciences. Direct peers are ArisGlobal, Endpoint Clinical (now part of Accenture) and United BioSource (UBC). Emerging players are AB Cube and Bio-Optronics.
Does Examoto have an API?
No public API is recorded for Examoto.
What industry is Examoto in?
Examoto's product category is Pharmaceutical Compliance Software. Its primary akta.pro industry code is HLAGAJAK, Pharmacovigilance & Drug Safety Software, with a secondary code of HLACAOAD, Clinical Trial Management Systems (CTMS). Its NAICS code is 541690 and its SIC code is 8731.